ORAL MODIFIED RELEASE FORMULATIONS

• US 20100086599A1
• Filed: 09/14/2007
• Published: 04/08/2010
• Est. Priority Date: 09/16/2006
• Status: Abandoned Application

• Current Assignee: Bayer Intellectual Property GmbH (Bayer AG)
• Original Assignee: Kairos Med GmbH
• Inventors: Thunecke, Markus, Heuermann, Arno, Krings, Matthias, Huempel, Michael, Schleuning, Wolf Dieter, Tack, Johannes
• Application Number:
  US12/441,195
• Publication Number:
  US 20100086599A1
• Time in Patent Office: Days
• US Class Current: 424/487
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 9/2072 characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms A61K9/0004, A61K9/0056, A61K9/0065 take precedence
• CPC Class Codes: A61P 15/12 for climacteric disorders
• CPC Class Codes: A61P 15/18 Feminine contraceptives
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/24 of the sex hormones

Abstract

This invention is directed to an oral modified release formulation of the phytoestrogen 8-Prenylnaringenin in combination with a progestin, preferably with Drospirenone, and several uses thereof. In another aspect of the invention an oral modified formulation of 8-Prenylnaringenin with an immediately releasing progestin, like Drospirenone, is provided as well as several uses thereof.

Claims

1. Oral modified release formulation containing 8-Prenylnaringenin, Drospirenone, a polymeric matrix, a buffer substance and one or more excipients.

3. Oral modified release formulation containing 8-Prenylnaringenin and Drospirenone according to claim 1 wherein the buffer substance is an alkaline substance.

4. Oral modified release formulation containing 8-Prenylnaringenin and Drospirenone according to claim 1 wherein said formulation is coated with a polymeric coat that affects the dissolution of active ingredients.

5. Oral modified release formulation according to claim 1 wherein the polymer matrix is chosen from the group of the following materials:

cellulose derivatives, acrylic derivatives, vinyl polymers, polyacrylates, polycarbonates, polyethers, polystyrenes polyanhydrides, polyesters, polyorthoesters, polysaccharides and natural polymers.

6. Oral modified release formulation according to claim 1 wherein the polymer matrix is chosen from water soluble polyvinylpyrrolidone and water insoluble polyvinylacetate.

7. Oral modified release formulation according to claim 1 wherein the buffer substance is magnesium oxide, magnesium hydroxide, dihydroxyaluminum aminoacetate, magnesium carbonate, calcium carbonate, sodium ascorbate, magnesium trisilicate, dihydroxyaluminum sodium carbonate, aluminum hydroxide, sodium citrate, potassium phosphate, sodium bicarbonate, disodium hydrogenphosphate or some combinations thereof.

8. Oral modified release formulation according to claim 1 wherein the formulation contains an additional lubricant.

9. Oral modified release formulation according to claim 1 wherein the excipient is lactose, calcium phosphate, manitol or starch.

10. Oral modified release formulation according to claim 1 wherein the formulation contains microcrystalline cellulose as an additional excipient.

11. Oral modified release formulation according to claim 1 wherein the formulation contains silicon dioxide as flow promoter.

12. Oral modified release formulation according to claim 1 wherein the particle size of the powder mixtures is between 20-400 [mu]m.

13. A method of using the oral modified release formulation according to claim 1 comprising producing a medicament for the combination hormonal contraception with said oral modified release formulation.

14. A method as in claim 13 where the oral modified release formulation has a preferred daytime ingestion of in the evening or bedtime.

15. A method as in claim 13 where the oral modified release formulation has an active treatment phase between 21 and 25 days.

16. A method of using the oral modified release formulation according to claim 1 comprising producing a medicament for the combination hormonal contraception with said oral modified release formulation where the preferred daytime of ingestion is the evening or bedtime.

17. A method of claim 16 which comprises producing a medicament for the treatment of symptoms of estrogen deficiency.

18. A method of claim 16 which comprises producing a medicament for the treatment of menopausal symptoms.

19. A method of claim 16 which comprises producing a medicament for the treatment of hot flushes.

20. A method of claim 16 which comprises producing a medicament for the combination hormone replacement therapy where the active treatment phase is between 21 and 25 days.

21. A method of claim 16 which comprises producing a medicament for the combination hormone replacement therapy where the active treatment phase is continuous.

22. A method as in claim 16 wherein 8-Prenylnaringenin is replaced by any other estrogenic compound or any derivative of 8-Prenylnaringenin.

23. A method as in claim 16 where Drospirenone is replaced by any other progestin or any derivative of Drospirenone

2. Oral modified release formulation containing 8-Prenylnaringenin, Drospirenone a polymeric matrix, a buffer substance and one or more excipients and where the particle size of the compounds is in the range of 0.1-750 [mu]m.

24. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part and where the modified releasing part contains a polymeric matrix, a buffer substance and one or more excipients.

26. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 and where the effective dose of 8-PN as well as of DRSP may be contained in one formulation unit or alternatively in two separate formulation parts and preferably packed and sealed together for example in one blister mould.

27. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the buffer substance is an alkaline substance.

28. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the modified releasing part is coated with a polymeric coat that affects the dissolution of 8-PN.

29. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the polymer matrix is chosen from the group of the following materials:

cellulose derivatives, acrylic derivatives, vinyl polymers, polyacrylates, polycarbonates, polyethers, polystyrenes polyanhydrides, polyesters, polyorthoesters, polysaccharides and natural polymers.

30. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the polymer matrix is chosen from water soluble polyvinylpyrrolidone and water insoluble polyvinylacetate.

31. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the buffer substance is magnesium oxide, magnesium hydroxide, dihydroxyaluminum aminoacetate, magnesium carbonate, calcium carbonate, sodium ascorbate, magnesium trisilicate, dihydroxyaluminum sodium carbonate, aluminum hydroxide, sodium citrate, potassium phosphate, sodium bicarbonate, disodium hydrogenphosphate or some combinations thereof.

32. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the preparation contains an additional lubricant.

33. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the excipient is lactose, polyvinylpyrrolidone, calcium phosphate, manitol, starch or modified starch.

34. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the preparation contains microcrystalline cellulose as an additional excipient.

35. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the preparation contains silicon dioxide as flow promoter.

36. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 wherein the particle size distribution of the powder mixtures is in a range between 2-400 [mu]m.

37. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 for the production of a medicament for the combination hormonal contraception.

38. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 for the production of a medicament for the combination hormone replacement therapy.

39. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 where the preferred daytime of ingestion is the evening or bedtime.

40. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 where the active oral contraceptive treatment phase is between 21 and 25 days.

41. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 where the active oral contraceptive treatment phase is between 21 and 25 days and where varying doses of DRSP and 8-PN are incorporated in the respective formulation parts during the active treatment period.

42. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 where the active oral hormone replacement therapy treatment phase is between 21 days and continuous.

43. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 where 8-Prenylnaringenin is replaced by any other estrogenic compound or any derivative of 8-Prenylnaringenin.

44. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part according to claim 24 where Drospirenone is replaced by any other progestin.

25. Two component oral preparation containing a modified releasing 8-PN part and an immediately DRSP releasing part and where the modified releasing part contains a polymeric matrix, a buffer substance and one or more excipients and where the particle size of the compounds is in the range of 0.1-750 [mu]m.